Quality of life in patients receiving treatment, for gynecologic malignancies: Special considerations for patient care

被引:33
作者
Wenzel, L
Vergote, I
Cella, D
机构
[1] Univ Calif Irvine, Coll Med, Epidemiol Div, Irvine, CA 92697 USA
[2] Univ Hosp Leuven, Dept Gynaecol Oncol, Louvain, Belgium
[3] Evanston Northwestern Healthcare & Northwestern U, Evanston, IL USA
关键词
quality of life; gynecologic malignancies; cervical; endometrial; ovarian; pain; sexual function; anemia; epoetin alfa;
D O I
10.1016/S0020-7292(03)90123-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Advances in the treatment of gynecologic cancer have extended the duration of survival of many patients. However, these patients frequently experience a variety of treatment- and disease-related side effects that diminish their quality of life (QOL) during and after treatment among these are pain, nausea and vomiting, anemia, fatigue, peripheral neuropathy, emotional distress, and sexual dysfunction. Given the gains in survival time, patient care is being expanded to include enhancement or preservation of QOL in addition to early diagnosis and disease treatment, thus treating the whole person. In parallel with this evolution in cancer care, supportive measures are being increasingly recognized as crucial to effective patient management. This paper reviews some of the potential causes of diminished QOL in gynecologic cancer patients and basic treatment strategies for their control, with a focus on short-term QOL issues. It is important that clinicians monitor QOL during the course of the disease and its treatment, utilize procedures and therapeutic agents that take patient preferences and QOL into account, and proactively prevent and treat relevant symptoms.
引用
收藏
页码:211 / 229
页数:19
相关论文
共 135 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   A COMPARISON OF THE TOXICITY AND EFFICACY OF CISPLATIN AND CARBOPLATIN IN ADVANCED OVARIAN-CANCER [J].
ADAMS, M ;
KERBY, IJ ;
ROCKER, I ;
EVANS, A ;
JOHANSEN, K ;
FRANKS, CR .
ACTA ONCOLOGICA, 1989, 28 (01) :57-60
[3]   Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[4]  
Almadrones L A, 1999, Oncol Nurs Forum, V26, P1359
[5]  
Andersen BL, 1999, MED PEDIATR ONCOL, V33, P15, DOI 10.1002/(SICI)1096-911X(199907)33:1<15::AID-MPO4>3.0.CO
[6]  
2-L
[7]  
ANNON JS, 1976, BEHAV TREATMENT SEXU, V1
[8]  
[Anonymous], WHO TECH REP SER
[9]   Relapsed ovarian cancer: Challenges and management strategies for a chronic disease [J].
Armstrong, DK .
ONCOLOGIST, 2002, 7 :20-28
[10]   Reliability and validity of the functional assessment of cancer therapy-ovarian [J].
Basen-Engquist, K ;
Bodurka-Bevers, D ;
Fitzgerad, MA ;
Webster, K ;
Cella, D ;
Hu, SH ;
Gershenson, DM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1809-1817